Dr. David Watson
Emergency Medicine (Emergency Medicine Physician)
36065 Santa Fe Ave
Fort Hood, TX 76544
Who else practices at this address →
Coryell County is a federal primary care shortage area. About shortage areas
At a glance
- In the NPI registry since
- 2021
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2021Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Emergency Medicine Physician primary
TX license BP10073679
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 1 companies reported 4 payments worth $2,064 in total to this clinician.
| AbbVie Inc. | $2,064 |
|---|
| Consulting Fee | $1,950 |
|---|---|
| Food and Beverage | $114 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Apr 9, 2025 | Consulting Fee | $1,200 |
| AbbVie Inc. Jan 23, 2025 | Consulting Fee | $750 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 1 companies. The companies reported $443,120 in research payments for these studies, mostly to the institutions running them.
- M22-721 - A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease
AbbVie Inc. - A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease
AbbVie Inc. · Completed · NCT05291234 - A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy
AbbVie Inc. - A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease
AbbVie Inc. - M23-515 - Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.